ESTIMATION OF CARDIOVASCULAR RISK IN PATIENTS WITH ULCERATIVE COLITIS ENROLLED IN UPADACITINIB PHASE 3 CLINICAL TRIALS

Laurent Peyrin-Biroulet

UEG Week Copenhagen 2023 | Poster

IBD

October 15, 2023

An analysis comparing cardiovascular risk profiles between ulcerative colitis patients in upadacitinib trials and rheumatoid arthritis patients in the ORAL Surveillance study found that the majority of UC patients had low estimated CV risk while the majority of RA patients were at intermediate or high CV risk.

KEY POINTS

- Of 1097 patients with UC from the U-ACHIEVE and U-ACCOMPLISH trials, 24.4% met ORAL Surveillance study inclusion criteria and 56.9% had at least one CV risk factor regardless of age.
- Only 2.7% of UC patients had a history of atherosclerotic cardiovascular disease, compared to 14.7% of RA patients in the ORAL Surveillance study.
- Among UC patients, 85.5% were categorized as low 10-year ASCVD risk, 4.7% borderline risk, 4.6% intermediate risk, and 2.4% high risk.
- The distribution of 10-year ASCVD risk scores was similar between placebo and upadacitinib 45 mg treatment arms in UC patients but markedly different from RA patients.
- The authors conclude that caution should be used when extrapolating adverse events data from patients with RA to risk discussions for patients with UC.

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/661469bc-743c-11ee-963b-0242ac140004

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.